In this installment of the "How I treat ..." series in Blood , the authors review treatment strategies for T-cell immunophenotype acute lymphoblastic leukemia (T-ALL). The authors note that using pediatric intensive combination chemotherapy regimens in adolescents and young adults has significantly improved the outcome of patients with T-ALL. The authors discuss using allogeneic hematopoietic cell transplantation (HCT) to treat T-ALL, and note that it can be appropriate for patients with high-risk or relapsed/refractory disease. They recommend that older and unfit patients receive upfront multi-agent chemotherapy, with allogeneic HCT as a second-line strategy based on their response, minimal residual disease status, risk factors, and comorbidities.
Review: Treating T-Cell ALL in Adults